Latest Breaking News On - Jason hafron - Page 1 : vimarsana.com

No PSA Recurrence at 24 Months With Apalutamide Plus ADT After Radical Prostatectomy

Biochemical control maintained despite high rates of testosterone recovery

Apalutamide/ADT Demonstrate s 100% Biochemical RFS Rate in High-Risk Prostate Cancer

Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.

Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

Article highlights results from successful Phase 2a clinical trial for lead candidate, LP-10 Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024 PITTSBURGH, Pa., Sept. 21,.

Lipella Pharmaceuticals' (LIPO) Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

How to Keep Your Practice Profitable Despite Staff Shortages

Many practices struggle with staff shortages, which affect billings, patient care, administrative tasks, and revenue issues. There are ways to prevent this.